Clinical Rheumatology

, Volume 29, Issue 5, pp 567–571 | Cite as

Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler’s syndrome: a case report and literature review

Case Report


We report a case of longstanding multidrug resistant Schnitzler’s syndrome that finally went into clinical remission upon treatment with anakinra and review the literature concerning IL1-RA treatment for Schnitzler’s syndrome. A now 71-year-old patient presenting with recurring episodes of urticaria and fever and secondary weight loss for the past 16 years as well as arthralgia, hearing loss. The patient has anemia, leucocytosis with neutrophilia, thrombocytosis, elevated C-reactive protein and erythrocyte sedimentation rate, lymphadenopathy and a monoclonal IgM kappa band that later became oligoclonal with two IgM kappa bands and one IgM lambda band. The patient was treated with moderate effect with combination of prednisolone, azathioprine, and colchicine. In March 2009, anakinra 100 mg daily sc was added during a disease flare. Within 24 h after the first injection, both the urticaria and the fever disappeared and have not recurred. For the past 6 months, the patient has been in clinical and biochemical remission. Colchicine has been stopped while the azathioprine and prednisolone doses are being reduced. Twenty-four patients with Schnitzler’s syndrome, including three patients with a variant of Schnitzler’s syndrome and three patients with a Schnitzler-like syndrome, have been successfully treated with anakinra. Nevertheless, seven out of seven patients, that either interrupted or used anakinra every other day, had relapse of their symptoms within 24-48 h; anakinra was restarted in all patients with the same clinical efficiency. The current case history and the literature review already suggest an important role for IL-1 as a mediator in the pathophysiology of Schnitzler’s syndrome.


Anakinra Autoinflammatory Monoclonal gammopathy Schnitzler syndrome Urticaria 


  1. 1.
    de Koning HD, Bodar EJ, van der Meer JWM, Simon A (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arhtritis Rheum 37:137–148CrossRefGoogle Scholar
  2. 2.
    Martinez-Taboada VM, Fontalba A, Blanco R, Fernández-Luna JL (2005) Successful treatment of refractory Schnizler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum 52(7):2226–2227CrossRefPubMedGoogle Scholar
  3. 3.
    de Koning HD, Bodar EJ, Simon A, van der Hilst JCH, Netea MG, van de Meer JWM. Beneficial response to anakinra and thalidomide in Schnizler’s syndrome. Ann Rheum Dis 65:542-544Google Scholar
  4. 4.
    Schneider SW, Gaubitz M, Luger TA, Bonsmann G. Prompt response of refractory Schnizler syndrome to treatment with anakinra. J Am Acad Dermatol 56(5):s120-s122Google Scholar
  5. 5.
    Treudler R, Kauer F, Simon JC. Striking effect of IL-1 receptor antagonist anakinra in chronic urticarial rash with polyclonal increase in IgA and IgG. Acta Derm Venereol 87:280-281Google Scholar
  6. 6.
    Crouch R, Akhras V, Sarkany R (2007) Schnitzler’s syndrome: successful treatment with anakinra. Australas J Dermatol 48:178–181CrossRefPubMedGoogle Scholar
  7. 7.
    Eiling E, Möller M, Kreiselmaier I, Brasch J, Schwarz T (2007) Schnizler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 57:361–364CrossRefPubMedGoogle Scholar
  8. 8.
    Klemmer N, Lenain P, Balguerie X, Le Loët X (2007) Effectiveness of anti-IL1 in Schnizler’s syndrome. Jt Bone Spine 74:509–510CrossRefGoogle Scholar
  9. 9.
    Thonhoffer R, Uitz E, Graninger W (2007) Schnitzler’s syndrome—exacerbation after anti-TNF treatment. Rheumatology 46:1041–1042CrossRefGoogle Scholar
  10. 10.
    Fernandez Flórez A, Gallardo Agromayor E, Garcia-Barredo R, Landeras Alvaro RM, Gorriño Angulo M, Martinez-Taboada VM et al (2008) Radiological aid to clinical diagnosis of Schnizler’s syndrome: multimodality imaging approach. Clin Rheumatol 27:107–110CrossRefGoogle Scholar
  11. 11.
    Gilson M, Abad S, Laroche C, Dhote R (2007) Treatment of Schnitzler’s syndrome with anakinra. Clin Exp Rheumatol 25(6):931PubMedGoogle Scholar
  12. 12.
    Eiling E, Schröder JO, Gross WL, Kreiselmaier I, Mrowietz U, Schwarz T (2008) The Schnitzler syndrome: chronic urticaria and monoclonal gammopathy—auto-inflammatory syndrome? JDDG 6:626–631CrossRefPubMedGoogle Scholar
  13. 13.
    Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A (2008) IL-1 blokade in Schnizler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 121(1):260–262CrossRefPubMedGoogle Scholar
  14. 14.
    Dybowski F, Sepp N, Bergerhausen HJ, Braun J (2008) Successful use of anakinra to treat refractory Schnitzler’s syndrome. Clin Exp Rheumatol 26:354–357PubMedGoogle Scholar
  15. 15.
    Devlin LA, Wright G, Edgar JDM (2008) A rare cause of a common symptom, Anakinra is effective in the urticaria of Schnizler syndrome: a case report. Cases Journal I:308Google Scholar
  16. 16.
    Kluger N, Rivière S, Guillot B, Bessis D (2008) Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory Schnitzler’s syndrome. Acta Derm Venereol 88:287–288CrossRefPubMedGoogle Scholar
  17. 17.
    Saiz E, Gálvez J, Mora A, Contreras L (2008) Sindrome de Schnitzler y anakinra. Med Clin (Barc) 130(9):357–358CrossRefGoogle Scholar
  18. 18.
    Frischmeyer-Guerrerio PA, Rachamalla R, Saini SS. Remission of Schnitzler syndrome after treatment with anakinra. Ann Allergy Asthma Immunol 100:617-619Google Scholar
  19. 19.
    Lazarevic V, Markuszewska A, Stenberg B, Häggroth J (2008) Schnitzlers syndrom—okänt, sällsynt med behandlingsbart. Läkartidningen 105:3348–3351PubMedGoogle Scholar
  20. 20.
    Wastiaux H, Barbarot S, Gagey-Caron V, Berthelot JM, Hamidou M, Stalder JF (2009) Schnitzler syndrome: a dramatic improvement with anakinra. JEADV 23:85–87PubMedGoogle Scholar
  21. 21.
    Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E (2001) The Schnitzler syndrome: four new cases and review of the literature. Medicine 80:37–44CrossRefPubMedGoogle Scholar
  22. 22.
    de Koning HD, van de Meer JWM, Simon A (2007) Comment on: Schnitzler’s syndrome—exacerbation after anti-TNF treatment. Rheumatology 46:1741CrossRefPubMedGoogle Scholar
  23. 23.
    Murota H, Shoda Y, Ishibashi T, Sugahara H, Matsumura I, Katayama I. Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy (2009) J Am Acad Dermatol (in press)Google Scholar
  24. 24.
    Dalle S, Balme B, Sebban C, Pariset C, Berger F, Thomas L (2006) Schnitzler syndrome associated with systemic marginal zone B-cell lymphoma. Br J Dermatol 155:827–829CrossRefPubMedGoogle Scholar
  25. 25.
    Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  1. 1.RheumatologyUniversity Hospital North NorwayTromsøNorway
  2. 2.Rheumatology, Institute of Clinical MedicineUniversity of TromsøTromsøNorway
  3. 3.Revmatologisk Avdeling, Nevro-og OrtopediklinikkenUniversitetssykehuset Nord-NorgeTromsøNorway

Personalised recommendations